| # | Title | Journal | Year | Citations |
|---|
| 1 | MET signalling: principles and functions in development, organ regeneration and cancer | Nature Reviews Molecular Cell Biology | 2010 | 1,029 |
| 2 | Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences | Nature Genetics | 2000 | 887 |
| 3 | Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up | Annals of Oncology | 2018 | 641 |
| 4 | Class 3 semaphorins control vascular morphogenesis by inhibiting integrin function | Nature | 2003 | 546 |
| 5 | Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells | Nature Medicine | 2003 | 539 |
| 6 | Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up | Annals of Oncology | 2018 | 413 |
| 7 | A Signaling Adapter Function for α6β4 Integrin in the Control of HGF-Dependent Invasive Growth | Cell | 2001 | 412 |
| 8 | Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆ | Annals of Oncology | 2021 | 381 |
| 9 | Bone sarcomas: ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up | Annals of Oncology | 2018 | 380 |
| 10 | Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers | Nature Medicine | 2019 | 359 |
| 11 | Lentiviral vectors: excellent tools for experimental gene transfer and promising candidates for gene therapy | Journal of Gene Medicine | 2000 | 318 |
| 12 | Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus | Journal of Clinical Investigation | 2010 | 309 |
| 13 | Adaptive mutability of colorectal cancers in response to targeted therapies | Science | 2019 | 290 |
| 14 | T helper type 17-related cytokine expression is increased in the bronchial mucosa of stable chronic obstructive pulmonary disease patients | Clinical and Experimental Immunology | 2009 | 283 |
| 15 | Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer | Cancer Discovery | 2016 | 258 |
| 16 | TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion–Positive Intrahepatic Cholangiocarcinoma | Cancer Discovery | 2019 | 254 |
| 17 | Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy | Nature Reviews Cancer | 2018 | 248 |
| 18 | EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer | Cancer Discovery | 2020 | 245 |
| 19 | How liquid biopsies can change clinical practice in oncology | Annals of Oncology | 2019 | 231 |
| 20 | Efficient Gene Delivery and Targeted Expression to HepatocytesIn Vivoby Improved Lentiviral Vectors | Human Gene Therapy | 2002 | 230 |
| 21 | Sema4D induces angiogenesis through Met recruitment by Plexin B1 | Blood | 2005 | 226 |
| 22 | Cancer therapy: can the challenge be MET? | Trends in Molecular Medicine | 2005 | 218 |
| 23 | Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial | Lancet Oncology, The | 2017 | 214 |
| 24 | Gastrointestinal stromal tumours: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up | Annals of Oncology | 2022 | 213 |
| 25 | Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial☆ | Annals of Oncology | 2020 | 206 |
| 26 | Metabolic pathways regulating colorectal cancer initiation and progression | Seminars in Cell and Developmental Biology | 2020 | 203 |
| 27 | Integrins and angiogenesis: A sticky business | Experimental Cell Research | 2006 | 186 |
| 28 | [26] Generation of HIV-1 derived lentiviral vectors | Methods in Enzymology | 2002 | 178 |
| 29 | ERK: A Key Player in the Pathophysiology of Cardiac Hypertrophy | International Journal of Molecular Sciences | 2019 | 168 |
| 30 | Machine learning-based prediction of adverse events following an acute coronary syndrome (PRAISE): a modelling study of pooled datasets | Lancet, The | 2021 | 164 |
| 31 | Evolving concepts in HER2 evaluation in breast cancer: Heterogeneity, HER2-low carcinomas and beyond | Seminars in Cancer Biology | 2021 | 162 |
| 32 | Tumor Evolution as a Therapeutic Target | Cancer Discovery | 2017 | 158 |
| 33 | Effective drug combinations in breast, colon and pancreatic cancer cells | Nature | 2022 | 154 |
| 34 | Tyrosine kinase signal specificity: lessons from the HGF receptor | Trends in Biochemical Sciences | 2003 | 153 |
| 35 | Bone sarcomas: ESMO–EURACAN–GENTURIS–ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up | Annals of Oncology | 2021 | 150 |
| 36 | NK-mediated antibody-dependent cell-mediated cytotoxicity in solid tumors: biological evidence and clinical perspectives | Annals of Translational Medicine | 2019 | 143 |
| 37 | High-dose vitamin C enhances cancer immunotherapy | Science Translational Medicine | 2020 | 143 |
| 38 | Commensal bacteria promote endocrine resistance in prostate cancer through androgen biosynthesis | Science | 2021 | 135 |
| 39 | Pro-metastatic signaling by c-Met through RAC-1 and reactive oxygen species (ROS) | Oncogene | 2006 | 125 |
| 40 | Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial | Lancet Oncology, The | 2021 | 120 |
| 41 | MiR-1 Downregulation Cooperates with MACC1 in Promoting MET Overexpression in Human Colon Cancer | Clinical Cancer Research | 2012 | 116 |
| 42 | In VivoTargeting of Tumor Endothelial Cells by Systemic Delivery of Lentiviral Vectors | Human Gene Therapy | 2003 | 114 |
| 43 | Molecular cancer therapy: Can our expectation be MET? | European Journal of Cancer | 2008 | 113 |
| 44 | Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma | Blood | 2011 | 113 |
| 45 | Predicting locally advanced rectal cancer response to neoadjuvant therapy with 18F-FDG PET and MRI radiomics features | European Journal of Nuclear Medicine and Molecular Imaging | 2019 | 113 |
| 46 | Scatter factors and invasive growth | Seminars in Cancer Biology | 2001 | 112 |
| 47 | Plasma HER2 (ERBB2) Copy Number Predicts Response to HER2-targeted Therapy in Metastatic Colorectal Cancer | Clinical Cancer Research | 2019 | 112 |
| 48 | Reactive Oxygen Species Mediate Met Receptor Transactivation by G Protein-coupled Receptors and the Epidermal Growth Factor Receptor in Human Carcinoma Cells | Journal of Biological Chemistry | 2004 | 108 |
| 49 | MicroRNA/gene profiling unveils early molecular changes and nuclear factor erythroid related factor 2 (NRF2) activation in a rat model recapitulating human hepatocellular carcinoma (HCC) | Hepatology | 2014 | 107 |
| 50 | Whose life to save? Scarce resources allocation in the COVID-19 outbreak | Journal of Medical Ethics | 2020 | 107 |
